The 2 most recent market catalysts affecting $IGC, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 26, 2026
Corporate Catalyst
Bullish
Impact 55
Ascendiant Capital Maintains Buy on IGC Pharma, Raises Price Target to $6
Ascendiant Capital analyst Edward Woo maintained a 'Buy' rating on IGC Pharma and raised the price target from $5.50 to $6. This analyst upgrade signals increased confidence in IGC…
Aug 17, 2026
Corporate Catalyst
Bearish
Impact 75
IGC Pharma Q2 EPS $(0.03) Misses $(0.02) Estimate, Sales $265.000K Beat $258.000K Estimate
IGC Pharma's Q2 results show a mixed performance. While the company missed EPS estimates significantly and saw a larger loss compared to the previous year, it also managed to beat …
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.